## Masaki Yamamoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/984145/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Digital PCR assay detection of circulating Mycobacterium tuberculosis DNA in pulmonary tuberculosis patient plasma. Tuberculosis, 2016, 99, 47-53.	1.9	59
2	Clinical significance of Charlson comorbidity index as a prognostic parameter for patients with acute or subacute idiopathic interstitial pneumonias and acute exacerbation of collagen vascular diseases-related interstitial pneumonia. Journal of Thoracic Disease, 2019, 11, 2448-2457.	1.4	25
3	Detection of Mycobacterium tuberculosis-derived DNA in circulating cell-free DNA from a patient with disseminated infection using digital PCR. International Journal of Infectious Diseases, 2018, 66, 80-82.	3.3	22
4	Identification of a novel biomarker based on lymphocyte count, albumin level, and TBAg/PHA ratio for differentiation between active and latent tuberculosis infection in Japan. Tuberculosis, 2020, 125, 101992.	1.9	13
5	MicroRNA â€200b is a potential biomarker of the expression of PDâ€L1 in patients with lung cancer. Thoracic Cancer, 2020, 11, 2975-2982.	1.9	12
6	Identification of Biomarkers for Non–small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor. Anticancer Research, 2020, 40, 3889-3896.	1.1	12
7	Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer. Internal Medicine, 2021, 60, 3593-3598.	0.7	8
8	Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with nonâ€smallâ€cell lung cancer: A multicenter retrospective trial. Thoracic Cancer, 2022, 13, 228-235.	1.9	7
9	Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pulmonary Enteric Adenocarcinoma. Cancer Diagnosis & Prognosis, 2022, 2, 253-257.	0.7	5
10	Hepcidin exerts a negative immunological effect in pulmonary tuberculosis without HIV co-infection, prolonging the time to culture-negative. International Journal of Infectious Diseases, 2019, 86, 47-54.	3.3	3
11	Reproducibility of the T-SPOT.TB test for screening Mycobacterium tuberculosis infection in Japan. Journal of Infection and Chemotherapy, 2020, 26, 194-198.	1.7	3
12	Class A CpG oligodeoxynucleotide inhibits IFNâ€Î³â€induced signaling and apoptosis in lung cancer. Thoracic Cancer, 2020, 11, 983-992.	1.9	3
13	Afatinib + bevacizumab combination therapy in EGFR â€mutant NSCLC patients with osimertinib resistance: Protocol of an openâ€label , phase II , multicenter, singleâ€arm trial. Thoracic Cancer, 2020, 11, 2125-2129.	1.9	2
14	A functionally improved case of obstructive impairment caused by systemic lupus erythematosus. Breathe, 2021, 17, 200288.	1.3	0
15	The Extent of Honeycombing on Computed Tomography Cannot Predict the Treatment Outcome of Patients with Acute Exacerbations of Interstitial Lung Disease. Canadian Respiratory Journal, 2021, 2021, 1-8.	1.6	0